肺癌局部区域复发胸部再程放疗的临床结局与毒性预测因素
该回顾性研究纳入50例2009至2017年间接受胸部再程放疗的肺癌患者,中位再程放疗剂量51.1 Gy(2 Gy分次等效剂量),中位局部进展时间18.0个月、无进展生存5.9个月、总生存25.1个月。肺V5、V20和平均肺剂量与≥2级肺毒性显著相关,7例(14%)发生致死性肺事件,再程放疗后化疗与致死性肺事件显著相关。
要点
- 胸部再程放疗可获得较好的局部控制,中位局部进展时间18.0个月。
- 肺V5、V20和平均肺剂量与≥2级肺毒性显著相关。
- 再程放疗后接受化疗与致死性肺事件显著相关(p=0.009)。
核心结论
- 胸部再程放疗对局部区域复发肺癌患者可获得较好的局部控制,但可能发生意外的致死性肺事件,尤其在再程放疗后接受全身治疗的患者中。
研究设计与样本
- 回顾性研究纳入50例2009至2017年间接受常规光子放疗和立体定向体部放疗(SBRT)的胸部再程放疗肺癌患者。
主要发现
- 再程放疗中位剂量为51.1 Gy(2 Gy分次等效剂量),平均计划靶区体积为201.58 ml。
- 中位平均肺剂量为4.18 Gy,全肺V5和V20分别为19.8%和5.85%。
- 局部进展时间、无进展生存和总生存分别为18.0、5.9和25.1个月。
- 肺V5(p < 0.001)、V20(p = 0.011)和平均肺剂量(p = 0.002)与≥2级肺毒性显著相关。
- 7例(14%)患者发生致死性肺事件,再程放疗后化疗与致死性肺事件显著相关(p = 0.009)。
临床怎么用
- 再程放疗计划时应关注肺V5、V20和平均肺剂量以评估≥2级肺毒性风险。
- 再程放疗后计划全身治疗时需警惕致死性肺事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Thoracic re-irradiation may be an alternative treatment for lung cancer patients who develop intrathoracic locoregional recurrence without systemic progression. This study aimed to retrospectively assess locoregional control, clinical outcomes, and toxicities in lung cancer patients who received thoracic re-irradiation. MATERIALS AND METHODS: We retrospectively reviewed 50 lung cancer patients who received thoracic re-irradiation using conventional photon radiotherapy (RT) and stereotactic body radiotherapy (SBRT) between 2009 and 2017. The correlations of clinicopathologic factors, treatment factors, and dosimetric factors of RT with time to local progression (TTLP), progression-free survival (PFS), and overall survival (OS) after starting thoracic re-irradiation were calculated using log-rank tests and Cox regression models. RESULTS: The median re-irradiation dose in equivalent dose in 2-Gy fractions was 51.1 Gy, and the mean re-irradiation planning target volume was 201.58 ml. The median mean lung dose (MLD) was 4.18 Gy, and the total lung volumes receiving a dose of 5 Gy (lung V5) and of 20 Gy (V20) were 19.8% and 5.85%, respectively. The TTLP, PFS, and OS were 18.0, 5.9, and 25.1 months, respectively. Lung V5 (p < 0.001), V20 (p = 0.011), and MLD (p = 0.002) were significantly associated with grade ≥2 lung toxicity. Seven (14%) patients developed lethal lung events. Subsequent chemotherapy following thoracic re-irradiation was significantly correlated with lethal lung events (p = 0.009). CONCLUSION: Promising local control can be achieved with thoracic re-irradiation in lung cancer patients with locoregional recurrence. However, unexpected lethal lung events may occur, especially in patients receiving systemic therapy following thoracic re-irradiation.
引用
- Yang WC, Hsu FM, Chen YH, et al. Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clin Transl Radiat Oncol. 2020. PMID: 32280792. doi:10.1016/j.ctro.2020.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。